Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 4Breast 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Gastrointestinal Neoplasms 1Fatigue 1Cognitive Dysfunction 1

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Methylphenidate × Breast × Clear all
NCT02970500 2023-03-23

CogMet

CHU de Quebec-Universite Laval

Phase 2 Terminated
20 enrolled
Breast

Breast Neoplasms, Cognitive Dysfunction

NCT00516269 2018-01-03

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
42 enrolled 8 charts
BreastGastrointestinal

Breast Neoplasms, Fatigue, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡